The global stem cells market is projected to expand from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, representing an 11.5% compound annual growth rate, according to Wissen Research. Growth is being driven by regenerative medicine, wider use of cell-based therapies, drug discovery, biomedical research, aging populations and rising chronic and degenerative disease burdens. Advances in cell acquisition, culture, expansion, processing and cryopreservation are improving the prospects for consistent commercial manufacturing. Induced pluripotent stem cells are attracting interest because they can be generated from adult tissue and developed into multiple cell types, while allogeneic, or donor-derived, therapies offer potential off-the-shelf scalability. Adult stem cells accounted for about 72% of 2025 revenue, pharmaceutical and biotechnology companies represented roughly 55% of end-user revenue, allogeneic therapies held approximately 60% of therapy revenue, and North America led regional markets with close to 44% share. Asia-Pacific is the fastest-growing region. The industry continues to face high manufacturing costs, demanding regulatory requirements, ethical considerations and shortages of specialized personnel. The forecast covers the broader stem cells market and is not directly comparable with the existing ResearchAndMarkets.com forecast for the narrower stem cell therapy market, which projects growth from USD 321 million in 2026 to USD 1.29 billion by 2035.